

Product Data Sheet

Inhibitors • Screening Libraries • Proteins

AMFR Protein, Human (Cell-Free, His)

Cat. No.:	HY-P702210		
Synonyms:	E3 ubiquitin-protein ligase AMFR; Autocrine motility factor receptor; AMF receptor; RING finger protein 45; gp78		
Species:	Human		
Source:	E. coli Cell-free		
Accession:	Q9UKV5 (M1-S643)		
Gene ID:	267		
Molecular Weight:	79.0 kDa		

PROPERTIES

AA Sequence						
An Sequence	MPLLFLERFP	WPSLRTYTGL	SGLALLGTII	SAYRALSQPE		
	AGPGEPDQLT	ASLQPEPPAP	ARPSAGGPRA	RDVAQYLLSD		
	SLFVWVLVNT	ACCVLMLVAK	LIQCIVFGPL	RVSERQHLKD		
	KFWNFIFYKF	IFIFGVLNVQ	TVEEVVMWCL	WFAGLVFLHL		
	MVQLCKDRFE	YLSFSPTTPM	SSHGRVLSLL	VAMLLSCCGL		
	AAVCSITGYT	Н G M H T L A F M A	AESLLVTVRT	AHVILRYVIH		
	LWDLNHEGTW	ЕGКGТҮVҮҮТ	DFVMELTLLS	LDLMHHIHML		
	LFGNIWLSMA	SLVIFMQLRY	LFHEVQRRIR	RHKNYLRVVG		
	NMEARFAVAT	PEELAVNNDD	CAICWDSMQA	ARKLPCGHLF		
	H N S C L R S W L E	QDTSCPTCRM	SLNIADNNRV	REEHQGENLD		
	ENLVPVAAAE	GRPRLNQHNH	FFHFDGSRIA	SWLPSFSVEV		
	MHTTNILGIT	Q A S N S Q L N A M	AHQIQEMFPQ	VPYHLVLQDL		
	QLTRSVEITT	DNILEGRIQV	PFPTQRSDSI	RPALNSPVER		
	PSSDQEEGET	SAQTERVPLD	LSPRLEETLD	FGEVEVEPSE		
	VEDFEARGSR	FSKSADERQR	MLVQRKDELL	QQARKRFLNK		
	SSEDDAASES	FLPSEGASSD	PVTLRRRMLA	AAAERRLQKQ		
	QTS					
A	the state of the s					
Appearance	Lyophilized powder.					
Formulation	Lyanhilized from a 0.22 um filtered colution of Tric/DBC based buffer (0). Trabalace all 0.0					
Formulation	Lyophilized from a 0.22 μm filtered solution of Tris/PBS-based buffer, 6% Trehalose, pH 8.0.					
Endotoxin Level	<1 FU/us determined by I AL method					
Endotoxin Level	<1 EU/µg, determined by LAL method.					
Reconsititution	It is not recommended to reconstitute to a concentration less than 100 μ g/mL in ddH ₂ O. For long term storage it is					
Reconstitution	recommended to add 5-50% of glycerol (final concentration). Our default final concentration of glycerol is 50%. Custo					
	could use it as reference.					
Storage & Stability	Stored at -20°C for 2 years. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It					
Storage & etablicy	recommended to freeze aliquots at -20°C or -80°C for extended storage.					

Shipping

Room temperature in continental US; may vary elsewhere.

DESCRIPTION

BackgroundAMFR, an E3 ubiquitin-protein ligase, orchestrates the polyubiquitination of target proteins, including CD3D, CYP3A4, CFTR,
INSIG1, SOAT2/ACAT2, and APOB, marking them for proteasomal degradation. As a component of the VCP/p97-AMFR/gp78
complex, it plays a pivotal role in the endoplasmic reticulum-associated degradation (ERAD) process, facilitating the
degradation of HMGCR and INSIG1 during sterol-accelerated ERAD. Through interaction with AUP1, AMFR engages with
ubiquitin-conjugating enzyme UBE2G2 and ubiquitin ligase RNF139, contributing to sterol-induced HMGCR ubiquitination
and subsequent degradation. Furthermore, AMFR participates in ubiquitination on cysteine residues, targeting
SOAT2/ACAT2 and INSIG2 for degradation under specific cellular conditions. Acting as a scaffold protein, AMFR assembles a
complex that couples ubiquitination, retranslocation, and deglycosylation. It serves as a receptor for GPI/autocrine motility
factor, promoting tumor invasion and metastasis. Moreover, in collaboration with LMBR1L and UBAC2, AMFR negatively
regulates the canonical Wnt signaling pathway by facilitating the ubiquitin-mediated degradation of CTNNB1 and Wnt
receptors FZD6 and LRP6, and it modulates NF-kappa-B and MAPK signaling pathways by mediating 'Lys-27'-linked
polyubiquitination of TAB3, leading to TAK1/MAP3K7 activation.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA